Gilead Sciences, Inc. (GILD) operating KPIs
GILDNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026Score 11/30105% above fair value
$170.68+5.07 (+3.06%)
Close on Oct 30, 2026Market cap $211.64BP/E –Yield 1.85%
Gilead Sciences arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M)
Arcus Biosciences (RCUS) Form 10-Q / 10-K
Latest, Q2 2026
36
Period ended Jun 30, 2026
Change on a year earlier
+140.0%
15 in Q2 2025
History
28 quarters
Since Q3 2019
Sources
27
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 36 | +140.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q1 2026 | Mar 31, 2026 | 3 | -80.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-05-05) ↗ |
| Q4 2025 | Dec 31, 2025 | 11 | -45.0% | Arcus Biosciences (RCUS) Form 10-Q (filed 2026-08-05) ↗ |
| Q3 2025 | Sep 30, 2025 | 11 | -31.2% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-10-28) ↗ |
| Q2 2025 | Jun 30, 2025 | 15 | -46.4% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-08-06) ↗ |
| Q1 2025 | Mar 31, 2025 | 15 | -57.1% | Arcus Biosciences (RCUS) Form 10-Q (filed 2025-05-06) ↗ |
| Q4 2024 | Dec 31, 2024 | 20 | -47.4% | Arcus Biosciences (RCUS) Form 10-K (filed 2026-02-25) ↗ |
| Q3 2024 | Sep 30, 2024 | 16 | -69.2% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-11-06) ↗ |
| Q2 2024 | Jun 30, 2024 | 28 | -17.6% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-08-08) ↗ |
| Q1 2024 | Mar 31, 2024 | 35 | +6.1% | Arcus Biosciences (RCUS) Form 10-Q (filed 2024-05-08) ↗ |
| Q4 2023 | Dec 31, 2023 | 38 | -2.6% | Arcus Biosciences (RCUS) Form 10-K (filed 2025-02-25) ↗ |
| Q3 2023 | Sep 30, 2023 | 52 | +90.5% | SEC Filing ↗ |
| Q2 2023 | Jun 30, 2023 | 34 | -5.0% | SEC Filing ↗ |
| Q1 2023 | Mar 31, 2023 | 33 | +12.2% | SEC Filing ↗ |
| Q4 2022 | Dec 31, 2022 | 39 | -94.8% | Arcus Biosciences (RCUS) Form 10-K (filed 2024-02-21) ↗ |
| Q3 2022 | Sep 30, 2022 | 27.3 | +2,933.3% | SEC Filing ↗ |
| Q2 2022 | Jun 30, 2022 | 35.8 | +2,137.5% | SEC Filing ↗ |
| Q1 2022 | Mar 31, 2022 | 29.4 | +465.4% | SEC Filing ↗ |
| Q4 2021 | Dec 31, 2021 | 745 | +67,627.3% | SEC Filing ↗ |
| Q3 2021 | Sep 30, 2021 | 0.90 | -65.4% | SEC Filing ↗ |
| Q2 2021 | Jun 30, 2021 | 1.60 | +700.0% | SEC Filing ↗ |
| Q1 2021 | Mar 31, 2021 | 5.20 | +1,633.3% | SEC Filing ↗ |
| Q4 2020 | Dec 31, 2020 | 1.10 | +1,000.0% | SEC Filing ↗ |
| Q3 2020 | Sep 30, 2020 | 2.60 | -50.9% | SEC Filing ↗ |
| Q2 2020 | Jun 30, 2020 | 0.20 | – | SEC Filing ↗ |
| Q1 2020 | Mar 31, 2020 | 0.30 | – | SEC Filing ↗ |
| Q4 2019 | Dec 31, 2019 | 0.10 | – | SEC Filing ↗ |
| Q3 2019 | Sep 30, 2019 | 5.30 | – | SEC Filing ↗ |
Cite this data
StockData. (2026). Gilead Sciences Arcus Biosciences — Unbilled receivables / contract asset from Gilead ($M) ($M), quarterly Q3 2019–Q2 2026 [Data set]. Compiled from Gilead Sciences SEC filings and investor materials. https://stockdatahq.com/stocks/gild/kpis/rcus_contract_asset
See every metric in the Gilead Sciences KPI table. Data updated Oct 29, 2026.